Just watched the webinar. Competent is the word that comes to...

Just watched the webinar. Competent is the word that comes to mind. A thorough presentation for the short 10 minute slot. They were very keen to expand on the essential differences between IPSC's and the standard pathway for MSC culture expansion, that they quite simply broke down to inter-donor variability and variability across the expansion process for investors, and where Cymerus removes essentially such variability and resolves the scale consistency issues.

Not too much that was not unknown to more informed CYP investors, but a very comprehensive summarising of where they are in everything. Happy to be corrected, but there appeared to be some new information on the DFU trial with some early graphed results from that trial showing around 70-80% success rate in DFU treatment from early results vs around 40% in SOC on the quick glimpse of the graph we were given - hopefully the company now posts the presentation for all to see and digest. I'd best quickly add that's a phase 1 trial and the sample sizes probably too small to be statistically significantly before I am accused of ramping/pumping.

Professional and concisely complete presentation. A bit of talk in the Q&A session of CYP's keen interest in out- licensing the technology to larger partners early in the clinical/commercial pathways to generate early revenues.